ElevenLabs $300M Secondary Tender

The key signal is that ElevenLabs did not need more cash to justify a higher price. In February 2026, investors put $500M of new money into the company at an $11B valuation. On September 30, 2026, the company instead ran a $300M employee tender at $22B, which means the money went to employees selling shares rather than onto the balance sheet. That is a different kind of vote of confidence, because buyers were paying up for access, not financing need.1 2 3 4

• This fits a pattern. ElevenLabs previously used secondaries to create liquidity, including a $100M tender in 2025 at a $6.6B valuation and another $100M tender in May 2026. The company has repeatedly let insiders sell stock without relying only on an IPO window.4 5 6
• Primary and secondary capital do different jobs. A primary round gives the company cash to hire researchers, buy compute, and expand internationally. A tender lets employees convert vested stock into cash, which helps retention by reducing pressure to leave or wait years for a public listing.2 3 6
• The backdrop is rapid operating momentum. ElevenLabs was at an estimated $600M annualized revenue by June 2026, up from $330M at the end of 2025, so the tender repricing happened while the business was already scaling fast. The higher valuation came alongside demand for scarce stock, not a rescue raise.5 6

Going forward, more of ElevenLabs financing mix is likely to look like this, big primary rounds when it wants to accelerate, then secondary liquidity programs as the company matures. That points toward a path where private investors and employees get regular liquidity before any eventual IPO, while the company preserves flexibility to raise only when it chooses to.1 2 4 6